ArticleContemporary oncology (Poznan, Poland)2013
Parameter identification of hematopoiesis mathematical model - periodic chronic myelogenous leukemia.
Article in Contemporary oncology (Poznan, Poland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodic chronic myelogenous leukemia (PCML) is a dynamic hematopoietic disease which causes oscillations of circulating leukocytes, platelets and reticulocytes. Mathematical modeling is an invaluable tool to help in predicting hematopoiesis behavior. In this paper we modify the existing models based on improving the parameters of the model. Also more parameters are estimated regarding the proposed model. It is our major intention to construct a physiological model which can map major identified mechanisms of leukopoiesis to provide a deeper insight into this complex biological process. In the proposed model the leukocytes line has been modeled more precisely. In fact, precursor cells have been considered as two separate groups: proliferating precursor cells and non-proliferating precursor cells. As a result, more parameters have appeared in the model and identifying the new parameters has resulted in a better fit of clinical data and the data extracted from the model for both platelets and leukocytes. That is, the new model describes the leukocytes and platelets of the system in a way that is closer to clinical data, so the proposed model can be more useful for predicting the behavior of leukocytes and platelets for PCML disease. Compared with the previous works, it is shown that the new model has a better fit of the quantitative data on leukocytes and platelets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.